Asieris(SH:688176)2023-09-25 02:10Group 1: Clinical Progress and Trials - APL-1202 is in clinical trials for treating high-risk NMIBC, with ongoing follow-up and recruitment for Phase II trials, aiming for mid-term analysis results [3] - APL-1706 has successfully completed a Phase III trial, achieving its primary endpoint of detecting additional bladder cancer lesions compared to white light endoscopy [4] - APL-1702 has completed statistical analysis for its Phase III trial, showing good safety and efficacy, with detailed results to be published in academic conferences [5] Group 2: Pricing Strategies - APL-1202's pricing will consider market characteristics, competitor pricing, patient accessibility, and insurance cooperation in China [3] - APL-1702 will reference costs of traditional surgical treatments for cervical pre-cancer patients when determining its pricing strategy [5] Group 3: Product Characteristics - APL-1702 is a photodynamic therapy product that integrates both drug and device elements, pending approval for drug classification [5]